Background: People living with HIV (PLWHIV) in Germany are facing new challenges in an aging society. The number of patients with multiple comedications is growing significantly.The US-American HIV-guidelines (DHHS) recommend treating PLWHIV in a multidisciplinary team, including pharmacist. This concept has not been implemented in Germany. Methods: 12-month prospective randomized case-control study to evaluate the influence of implementing a pharmacist to an interdisciplinary HIV-care provider team. The role of the pharmacist included assesing comedications and dietary supplements and optimizing the daily medication schedule. Main endpoints changes in imunologic markers such as CD4-cell count and the number of dietary supplements and their influence on the antiretroviral therapy. Results: 37 Patients were recruted for the study. 19 Patients received intervention by the pharmacist, 18 patients were randomized to the control group, which did not receive intervention by the pharmacist. Mean number of comedications in both groups was 5. In 10,5% of the patients in the intervention group use of dietary supplements was detected, which were contraindicated in combination with ART. Immunologic markers showed a tendency to improve in the intervention group after 6 month, but this difference could not be detected significantly.

No abstract

Background Cutaneous melanoma is an aggressive cancer that occurs in melanocytes, located in the epidermis. Historically it has a high rate of morbidity and mortality, due to the resistance and toxicity of traditional therapies. Its incidence has increased annually by 4% to 8%. Until 2011 it was still considered a devastating and almost always fatal disease in a few months. Advances in therapies have significantly improved the results of most patients with advanced melanoma, especially those with a BRAFV600 mutation, which account for almost 50% of tumors. Before the recent evolution in treatment, the prognosis and overall survival were considered very bad. The introduction of new drugs has improved progression-free survival and overall survival, as well as producing faster clinical responses. Methods Comparison of endpoints such as progression-free survival and overall melanoma survival from the Summary of Product Characteristics (SPC) studies of each drug in the therapeutic groups under assessment used in the disease. The variables used were the Endpoints Global Survival at various times (12 months, 24 months, 36 months and the median) and Progression-Free Survival. Results Combined immunotherapy (Nivolumab and Ipilimumab) improves overall survival and progression-free survival, achieving better results than targeted therapy. In this, the combination of a BRAF inhibitor and a MEK inhibitor, presents better results with the combination of Encorafenib and Binimetinib. Conclusions Both targeted therapy and immunotherapy transform melanoma with a dismal prognosis into a life-threatening illness.